Hikma intros generic Xyrem

Hikma is offering an authorized generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution CIII.

Hikma will have 180 days of marketing exclusivity for its authorized generic product in the United States, the company said.

[Read more: Hikma intros 2 injectables]

Sodium oxybate oral solution is used to treat narcolepsy, sudden onset of weak or paralyzed muscles (cataplexy) and excessive daytime sleepiness in individuals aged 7 years old and older. 

Xyrem had a market value of $1.3 billion in 2021, Hikma noted.

[Read more: Hikma to acquire Custopharm]

“We are pleased to be able to provide the first authorized generic version of Xyrem to patients and healthcare providers in the United States," said Brian Hoffmann, president of Hikma generics. This launch further expands our diversified portfolio of generic products, and underscores our ability to put ‘Better Health, Within Reach, Every Day’ for the millions of people who rely on our medicines.”